 ENGLEWOOD, Colo., June 17, 2021 PRNewswire -- Ampio Pharmaceuticals NYSE American: AMPE, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today reported newly integrated data from four of its earlier clinical trials with consistent inclusion, exclusion, and demographic populations utilizing Ampion for treating osteoarthritis of the knee OAK. 